Pharmaids Pharma

{
  "main_header": {
    "sid": 799751,
    "name": "Pharmaids Pharma",
    "stock_name": "Pharmaids Pharma",
    "full_name": "Pharmaids Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/pharmaids-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "33.00",
    "chg": -0.17,
    "chgp": "-0.51%",
    "dir": -1,
    "prev_price": "33.17",
    "mcapval": "118.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524572,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE117D01018",
    "curr_date": "Jul 17, 03:30 PM",
    "curr_time": "02:16 AM",
    "last_traded_at": "Jul 17, 03:30 PM IST",
    "bse_nse_vol": "6.58 k",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2026",
    "traded_date_str": "2026 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pharmaids-pharma-799751-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-4093425",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/PharmaidsPharma_mojoScore_4093425.png",
        "date": "2026-07-08 10:10:56",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-4074934",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PharmaidsPharma_mojoScore_4074934.png",
        "date": "2026-06-27 10:10:34",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 27 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-4055829",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PharmaidsPharma_mojoScore_4055829.png",
        "date": "2026-06-16 10:11:10",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Pharmaids Pharmaceuticals Declines 8.97%: Key Financial and Market Pressures This Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pharmaids-pharmaceuticals-declines-897-key-financial-and-market-pressures-this-week-4052218",
        "imagepath": "",
        "date": "2026-06-13 17:08:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jun 01:</strong> Stock hits 52-week low at Rs.25.6 amid sharp decline</p>\n                    <p><strong>Jun 02:</strong> Q4 FY26 results reveal mounting losses despite revenue growth</p>\n                    <p><strong>Jun 05:</strong> Week closes at Rs.27.62, down 8.97% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.30.34</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.27.62</div><div class=\"stat-change negative\">-8.97%</div></div>\n                    <div class=\"sta..."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-4033580",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PharmaidsPharma_mojoScore_4033580.png",
        "date": "2026-06-03 10:10:33",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 03 June 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Are Pharmaids Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-pharmaids-pharmaceuticals-ltd-latest-results-good-or-bad-4032438",
        "imagepath": "",
        "date": "2026-06-02 19:33:55",
        "description": "Pharmaids Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal a complex picture of revenue growth juxtaposed against ongoing operational challenges. The company reported net sales of ₹7.18 crores, reflecting a 32.23% sequential increase from ₹5.43 crores in Q3 FY26 and a significant 50.52% rise year-on-year from ₹4.77 crores in Q4 FY25. However, this topline growth has not translated into profitability, as the company continues to face substantial net losses, with a consolidated net loss of ₹1.81 crores in Q4 FY26, which is a reduction from previous quarters but still indicative of ongoing financial distress.\n\nThe operating margin for the quarter was recorded at -4.74%, an improvement from -46.04% in Q3 FY26, yet it remains firmly in negative territory. This suggests that while there has been some operational progress, the company is still grappling with structural inefficiencies that hinder i..."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd Falls to 52-Week Low of Rs 25.6 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pharmaids-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs256-4026324",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PharmaidsPharma_priceRelatedfactors_4026324.png",
        "date": "2026-06-01 10:35:26",
        "description": "A sharp decline of 15.62% in intraday trading dragged Pharmaids Pharmaceuticals Ltd to a fresh 52-week low of Rs 25.6 on 1 Jun 2026, extending its downward trajectory amid persistent selling pressure."
      },
      {
        "title": "Pharmaids Pharmaceuticals Q4 FY26: Mounting Losses Despite Revenue Growth Signal Deep Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/pharmaids-pharmaceuticals-q4-fy26-mounting-losses-despite-revenue-growth-signal-deep-operational-crisis-4031013",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PharmaidsPharma_quaterlyResult_4031013.png",
        "date": "2026-05-30 16:47:24",
        "description": "Pharmaids Pharmaceuticals Ltd., a Hyderabad-based contract research and manufacturing services company, reported its Q4 FY26 results that reveal a troubling paradox: robust revenue growth coupled with deteriorating profitability. The micro-cap pharmaceutical firm posted a consolidated net loss of ₹1.81 crores for the March 2026 quarter, marking a 27.02% sequential decline and a 54.06% year-on-year deterioration, even as net sales surged 50.52% YoY to ₹7.18 crores."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-4004853",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PharmaidsPharma_mojoScore_4004853.png",
        "date": "2026-05-22 10:10:58",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      }
    ],
    "total": 126,
    "sid": "799751",
    "stock_news_url": "https://www.marketsmojo.com/news/pharmaids-pharmaceuticals-799751"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jul-2026",
      "details": "Certificate under Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations 2018 for the quarter ended June 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "30-Jun-2026",
      "details": "Appointment of M/s. V Mahendra & Associates as the Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "25-Jun-2026",
      "details": "Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you of the change in Senior Management Personnel of the Company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-07-08 10:10:56

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-06-27 10:10:34

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 27 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-06-16 10:11:10

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Pharmaids Pharmaceuticals Declines 8.97%: Key Financial and Market Pressures This Week

2026-06-13 17:08:31

Key Events This Week

Jun 01: Stock hits 52-week low at Rs.25.6 amid sharp decline

Jun 02: Q4 FY26 results reveal mounting losses despite revenue growth

Jun 05: Week closes at Rs.27.62, down 8.97% for the week

Week Open

Rs.30.34

Week Close

Rs.27.62

-8.97%

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-06-03 10:10:33

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 03 June 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Are Pharmaids Pharmaceuticals Ltd latest results good or bad?

2026-06-02 19:33:55

Pharmaids Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal a complex picture of revenue growth juxtaposed against ongoing operational challenges. The company reported net sales of ₹7.18 crores, reflecting a 32.23% sequential increase from ₹5.43 crores in Q3 FY26 and a significant 50.52% rise year-on-year from ₹4.77 crores in Q4 FY25. However, this topline growth has not translated into profitability, as the company continues to face substantial net losses, with a consolidated net loss of ₹1.81 crores in Q4 FY26, which is a reduction from previous quarters but still indicative of ongoing financial distress. The operating margin for the quarter was recorded at -4.74%, an improvement from -46.04% in Q3 FY26, yet it remains firmly in negative territory. This suggests that while there has been some operational progress, the company is still grappling with structural inefficiencies that hinder i...

Read full news article

Pharmaids Pharmaceuticals Ltd Falls to 52-Week Low of Rs 25.6 as Sell-Off Deepens

2026-06-01 10:35:26

A sharp decline of 15.62% in intraday trading dragged Pharmaids Pharmaceuticals Ltd to a fresh 52-week low of Rs 25.6 on 1 Jun 2026, extending its downward trajectory amid persistent selling pressure.

Read full news article

Pharmaids Pharmaceuticals Q4 FY26: Mounting Losses Despite Revenue Growth Signal Deep Operational Crisis

2026-05-30 16:47:24

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based contract research and manufacturing services company, reported its Q4 FY26 results that reveal a troubling paradox: robust revenue growth coupled with deteriorating profitability. The micro-cap pharmaceutical firm posted a consolidated net loss of ₹1.81 crores for the March 2026 quarter, marking a 27.02% sequential decline and a 54.06% year-on-year deterioration, even as net sales surged 50.52% YoY to ₹7.18 crores.

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-05-22 10:10:58

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

View All News